Stock Events

Stock Events

Telix Pharmaceuticals 

$9.24
101
-$0.33-3.45% Today

Statistics

Day High
9.41
Day Low
9.2
52W High
20
52W Low
6.28
Volume
156,341
Avg. Volume
247,288
Mkt Cap
3.13B
P/E Ratio
533
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 6
$0.04
Jan 6
$0.04
Oct 5
$0.04
Jul 5
$0.04
Apr 5
$0.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19FebExpected
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.01
0.04
0.09
0.13
Expected EPS
0.032767
Actual EPS
-0.0116

Financials

-0.89%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.07BRevenue
-9.48MNet Income

Analyst Ratings

$21.25Average Price Target
The highest estimate is 22.50.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TLX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alternative Access First Priority CLO Bond
AAA
Mkt Cap0
Advanced Accelerator Applications, a Novartis company, competes in the radiopharmaceuticals market for diagnostic and therapeutic applications, similar to Telix's focus area.
ClearPoint Neuro
CLPT
Mkt Cap660.08M
ClearPoint Neuro, Inc. specializes in precision delivery of therapeutics to the brain, competing in the neuro-oncology segment where Telix also operates.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its acquisitions and internal development, competes across a broad range of therapeutic areas including those targeted by Telix's radiopharmaceuticals.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies Inc. has a diverse portfolio that includes products competing in the oncology and radiopharmaceutical sectors.
Protagonist Therapeutics
PTGX
Mkt Cap4.89B
Protagonist Therapeutics, Inc. is involved in the development of peptide-based therapeutics, competing in the innovative treatment space including cancer, where Telix is also active.
Dr. Reddy`s Laboratories
RDY
Mkt Cap11.25B
Dr. Reddy’s Laboratories Ltd. manufactures and markets a wide range of pharmaceuticals globally, including generic versions of drugs that compete with Telix's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company operates in the oncology space with a broad portfolio of drugs that compete with Telix Pharmaceuticals in the cancer treatment market.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company has a strong presence in oncology and radiopharmaceuticals, directly competing with Telix in several therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a global pharmaceutical giant with a diverse portfolio, including oncology and radiopharmaceuticals, making it a competitor in multiple areas relevant to Telix.

About

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Show more...
CEO
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA
Country
US
ISIN
US87961M1053

Listings

MX
MX
TLX1N.MX
F
DE
T3X0.F
OTC Link
US
TLPPF
XNAS
US
TLX

0 Comments

Share your thoughts

FAQ

What is Telix Pharmaceuticals stock price today?▼
The current price of TLX is $9.24 USD — it has decreased by -3.45% in the past 24 hours. Watch Telix Pharmaceuticals stock price performance more closely on the chart.
What is Telix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Telix Pharmaceuticals stocks are traded under the ticker TLX.
Is Telix Pharmaceuticals stock price growing?▼
TLX stock has risen by +3.82% compared to the previous week, the month change is a +27.45% rise, over the last year Telix Pharmaceuticals has showed a -44.7% decrease.
What is Telix Pharmaceuticals market cap?▼
Today Telix Pharmaceuticals has the market capitalization of 3.13B
When is the next Telix Pharmaceuticals earnings date?▼
Telix Pharmaceuticals is going to release the next earnings report on August 20, 2026.
What were Telix Pharmaceuticals earnings last quarter?▼
TLX earnings for the last quarter are -0.01 USD per share, whereas the estimation was 0.03 USD resulting in a -135.4% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Telix Pharmaceuticals revenue for the last year?▼
Telix Pharmaceuticals revenue for the last year amounts to 1.07B USD.
What is Telix Pharmaceuticals net income for the last year?▼
TLX net income for the last year is -9.48M USD.
Does Telix Pharmaceuticals pay dividends?▼
Yes, TLX dividends are paid quarterly. The last dividend per share was 0.04 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Telix Pharmaceuticals complete a stock split?▼
Telix Pharmaceuticals has not had any recent stock splits.
Where is Telix Pharmaceuticals headquartered?▼
Telix Pharmaceuticals is headquartered in North Melbourne, US.